5975-12-2

Basic information

• Product Name: 2,4-Dichloro-3-nitropyridine
• Synonyms: Pyridine, 2,4-dichloro-3-nitro-;2,4-dichloronitro pyridine;2,4-Dichloro-3-nitropyridine-2;2,4-Dichloro-3-nitropyridine;4-dichloro-3-nitro-
• CAS NO: 5975-12-2
• Molecular Formula: C₅H₂Cl₂N₂O₂
• Molecular Weight: 192.99
• EINECS: 224-340-6
• Product Categories: Heterocycle-Pyridine series;Pyridine Series;Pyridine
• Mol File: 5975-12-2.mol
• Article Data: 27

Chemical Properties

• Melting Point: 61.5-62 °C
• Boiling Point: 285.709 °C at 760 mmHg
• Flash Point: 126.593 °C
• Appearance: Light yellow needles
• Density: 1.63 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -2.49±0.10(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-3-nitropyridine(5975-12-2)
• EPA Substance Registry System: 2,4-Dichloro-3-nitropyridine(5975-12-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• HazardClass: IRRITANT
• Hazardous Substances Data: 5975-12-2(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow needles

Uses

2,4-Dichloro-3-nitropyridine is a reactant in the discovery of Imigliptin, a novel selective dipeptidyl peptidase IV (DPP-4) inhibitor used in the treatment of type 2 diabetes.

InChI:InChI=1/C5H2Cl2N2O2/c6-3-1-2-8-5(7)4(3)9(10)11/h1-2H

Upstream product

• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 626-03-9 3-deazauracil 
• 5466-62-6 4,6-dihydroxy-nicotinic acid 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 685542-71-6 MB₂₁₈₃₃ 
• 6317-97-1 ethyl 2,4-dihydroxy-3-nitropyridine-5-carboxylate 
• 89282-12-2 4-hydroxy-3-nitro-2(1H)-pyridone 
• 165547-79-5 2-hydroxy-3-nitro-4-chloropyridine 

Downstream Products

• 173772-63-9 2,4-dichloropyridin-3-ylamine 
• 24501-21-1 2,4-diamino-3-nitropyridine 
• 881844-09-3 2-chloro-N-(4-methoxybenzyl)-3-nitropyridin-4-amine 
• 3243-26-3 4-hydrazino-1H-imidazo[4,5-c]pyridine 
• 881844-12-8 4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine 
• 881844-11-7 4-chloro-1-(p-methoxybenzyl)-1H-imidazo[4,5-c]pyridine 
• 881844-10-6 2-chloro-N⁴-(4-methoxybenzyl)pyridine-3,4-diamine 
• 881844-13-9 4-amino-1-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-1H-imidazo[4,5-c]pyridine 
• 881844-18-4 4-amino-3-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-3H-imidazo[4,5-c]pyridine 
• 6811-77-4 3-deazaadenine 
• 629655-39-6 tert-butyl 2-[2-({2-[5-chloro-2-(1H-1,2,4-triazol-1-yl)benzyl][1,3]oxazolo[4,5-c]pyridin-4-yl}amino)ethyl]piperidine-1-carboxylate 
• 629655-38-5 tert-butyl 2-(2-{[3-({[5-chloro-2-(1H-1,2,4-triazol-1-yl)phenyl]acetyl}amino)-4-hydroxypyridin-2-yl]amino}ethyl)piperidine-1-carboxylate 
• 179056-98-5 3-amino-2,4-dichloro-6-methylpyridine 
• 237435-16-4 6-bromo-2,4-dichloropyridin-3-ylamine 

Relevant articles and documents

IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME

One aspect of the present invention provides a compound selected from among a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically accep

1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway

The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use in the clinic and the drug-drug interactions with rifampicin have prompted research efforts towards identifying alternative ATP synthesis inhibitors with differentiated mechanisms of action. A biochemical assay was employed to screen AstraZeneca's corporate compound collection to identify the inhibitors of mycobacterial ATP synthesis. The high-throughput screening resulted in the identification of 2,4-diaminoquinazolines as inhibitors of the ATP synthesis pathway. A structure-activity relationship for the quinazolines was established and the knowledge was utilized to morph the quinazoline core into quinoline and pyrazolopyrimidine to expand the scope of chemical diversity. The morphed scaffolds exhibited a 10-fold improvement in enzyme potency and over 100-fold improvement in selectivity against inhibition of mammalian mitochondrial ATP synthesis. These novel compounds were bactericidal and demonstrated growth retardation of Mycobacterium tuberculosis in the acute mouse model of tuberculosis infection.